Please assess the completion status of the following clinical trial:

Trial Title: A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-cell Chronic Lymphocytic Leukemia (B-CLL) according to the 1996 National Cancer Institute-sponsored Working Group (NCI-WG) Criteria~* One or more, but \<= 3 previous treatment regimens for Chronic Lymphocytic Leukemia (CLL)~* Patient requires treatment for CLL (Rai stage III and IV disease or stage 0 to II disease with evidence of progression)~* Adequate bone marrow, liver and renal function~* More than 4 weeks since prior chemotherapy or chemoimmunotherapy, including investigational agents, for the treatment of CLL. Patient must have recovered from the acute side effects incurred as a result of previous therapy~* World Health Organization (WHO) Performance Status (PS) 0,1~* Life expectancy of at least 24 weeks~* Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 2 weeks after the completion of trial~* Written informed consent~Exclusion Criteria:~* Known human immunodeficiency virus (HIV) seropositivity~* Active hepatitis or a history of prior viral hepatitis B or hepatitis C, or positive hepatitis B serologies. Patients with a positive hepatitis B surface antibody (HBsAb) test with a documented history of prior hepatitis B immunization are eligible as long as other criteria are met (i.e., negative tests for : hepatitis B surface antigen \[HBsAg\], hepatitis B core antibody \[HBcAb\] and hepatitis C virus antibody \[HCVAb\])~* Active uncontrolled infection~* Recent documented history (within 2 years) of active tuberculosis (TB), current active TB infection, currently receiving anti-tuberculous medication (e.g., isoniazid, rifampin, streptomycin, pyrazinamide, or others)~* Positive cytomegalovirus (CMV) by Polymerase Chain Reaction (PCR) assay~* Transformation to aggressive lymphoma (e.g., Richter's syndrome)~* Past history of anaphylaxis following exposure to humanized monoclonal antibodies~* Previous treatment with alemtuzumab~* Previous hematopoietic stem cell transplant~* Pregnant or breast-feeding patients~* Central nervous system (CNS) involvement with CLL~* Other severe, concurrent diseases (e.g., cardiac or pulmonary disease), mental disorders, or major organ malfunction (e.g., liver, kidney) that could interfere with the patient's ability to participate in the study~* Medical condition requiring chronic use of oral corticosteroids at a dose higher than physiologic replacement.~* Active malignancy, other than CLL, which needs therapy with anti-cancer drug(s)~* Autoimmune anemia and/or thrombocytopenia~* Small lymphocytic lymphoma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab (Type: EXPERIMENTAL): The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).

Based on this trial design, predict the completion outcome and termination type (if applicable).